ArticleF1000 medicine reports2009
Therapeutic options for lymphangioleiomyomatosis (LAM): where we are and where we are going.
Article in F1000 medicine reports, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- Effects of Sirolimus on Lung function in patients with Lymphangioleiomyomatosis.Caspian journal of internal medicine · 2019Article
- Familial syndromes associated with intracranial tumours: a review.Child's nervous system : ChNS : official journal of the International Society for Pediatric Neurosurgery · 2014Review
- Lymphangioleiomyomatosis: current and future.Journal of thoracic disease · 2013Article
- [A clinicopathological analysis of pulmonary lymphangioleiomyomatosis].Zhongguo fei ai za zhi = Chinese journal of lung cancer · 2011Article
- Progress in the treatment of lymphangioleiomyomatosis: from bench to bedside.Revista portuguesa de pneumologiaArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Lymphangioleiomyomatosis (LAM), a multisystem disease affecting predominantly premenopausal and middle-aged women, causes progressive respiratory failure due to cystic lung destruction and is associated with lymphatic and kidney tumors. In the past, the treatment of LAM comprised exclusively anti-estrogen and related hormonal therapies. These treatments, however, have not been proven effective. In this article, we discuss new findings regarding the molecular mechanisms involved in the regulation of LAM cell growth, which may offer opportunities to develop effective and targeted therapeutic agents.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.